Flex Pharma Inc.

The momentum for this stock is not very good. Flex Pharma Inc. is not a good value stock. Flex Pharma Inc. is not a good growth stock. Flex Pharma Inc. is a mediocre stock to choose.

News

Salarius Pharmaceuticals (NASDAQ:SLRX) Stock Price Up 0.7%

Zolmax Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX - Get Free Report)'s stock price traded up 0.7% during mid-day trading on Wednesday . The company traded as high as $1.61 and last traded at $1.51. 35,889...\n more…

Salarius Pharmaceuticals (NASDAQ:SLRX) Trading Up 0.7%

Ticker Report Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX - Get Free Report) shares traded up 0.7% on Wednesday . The company traded as high as $1.61 and last traded at $1.51. 35,889 shares changed hands during...\n more…

SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nSLRX stock results show that Salarius Pharmaceuticals beat analyst estimates for earnings per share the second quarter of 2024.\nThe post...\n more…

Why Is Salarius Pharmaceuticals (SLRX) Stock Up 90% Today?

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nWhile Salarius Pharmaceuticals encountered a hiccup in its genomics research, the possibility of new funding may have lifted SLRX...\n more…

Salarius Pharmaceuticals announces presentation of data on seclidemstat

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting

Globe Newswire Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported a 43% overall response rate among 14...\n more…